Neoantigen, Pancreatic Cancer, iNeo-Vac-P01,Peptide Vaccine
Showing 1 - 25 of >10,000
Pancreatic Cancer, Pancreatic Carcinoma Trial in Hangzhou (iNeo-Vac-P01, GM-CSF)
Completed
- Pancreatic Cancer
- Pancreatic Carcinoma
- iNeo-Vac-P01
- GM-CSF
-
Hangzhou, Zhejiang, ChinaZhejiang Provincial People's Hospital
Nov 15, 2021
Digestive System Tumors Trial in Hangzhou (iNeo-Vac-R01)
Recruiting
- Digestive System Neoplasms
- iNeo-Vac-R01
-
Hangzhou, Zhejiang, ChinaDepartment of General Surgery, Institute of Minimally Invasive S
Sep 8, 2023
Resectable Pancreatic Cancer Trial in Hangzhou (iNeo-Vac-P01, GM-CSF)
Recruiting
- Resectable Pancreatic Cancer
- iNeo-Vac-P01
- GM-CSF
-
Hangzhou, Zhejiang, ChinaZhejiang Provincial People's Hospital
Nov 15, 2021
Digestive System Tumors Trial in Hangzhou (iNeo-Vac-R01 in combination with standard adjuvant therapy)
Recruiting
- Digestive System Neoplasms
- iNeo-Vac-R01 in combination with standard adjuvant therapy
-
Hangzhou, Zhejiang, ChinaDepartment of General Surgery, Institute of Minimally Invasive S
Sep 8, 2023
Digestive System Tumors Trial in Hangzhou (iNeo-Vac-R01)
Recruiting
- Digestive System Neoplasms
- iNeo-Vac-R01
-
Hangzhou, Zhejiang, ChinaDepartment of General Surgery, Institute of Minimally Invasive S
Sep 8, 2023
Advanced Malignant Solid Tumor Trial in Hangzhou (iNeo-Vac-P01, GM-CSF)
Active, not recruiting
- Advanced Malignant Solid Tumor
- iNeo-Vac-P01
- GM-CSF
-
Hangzhou, Zhejiang, ChinaSir Run Run Shaw Hospital
Nov 15, 2021
Resectable Esophageal Cancer Trial in Hangzhou (iNeo-Vac-P01, GM-CSF)
Recruiting
- Resectable Esophageal Cancer
- iNeo-Vac-P01
- GM-CSF
-
Hangzhou, Zhejiang, ChinaThe Second Affiliated Hospital of Zhejiang University
Mar 23, 2022
Pancreas Cancer, Pancreatic Cancer, Cancer of the Pancreas Trial in Saint Louis (Optimized neoantigen synthetic long peptide
Recruiting
- Pancreas Cancer
- +2 more
- Optimized neoantigen synthetic long peptide vaccine
- Poly-ICLC
-
Saint Louis, MissouriWashington University School of Medicine
Jan 23, 2023
Pancreas Cancer, Pancreatic Cancer, Cancer of the Pancreas Trial in Saint Louis (biological, drug, procedure)
Recruiting
- Pancreas Cancer
- +2 more
- Neoantigen Peptide Vaccine
- +2 more
-
Baltimore, Maryland
- +1 more
Mar 15, 2022
Pancreatic Cancer Metastatic, Colorectal Cancer Metastatic Trial in Baltimore (Neoantigen Vaccine with Poly-ICLC adjuvant,
Not yet recruiting
- Pancreatic Cancer Metastatic
- Colorectal Cancer Metastatic
- Neoantigen Vaccine with Poly-ICLC adjuvant
- Retifanlimab
-
Baltimore, MarylandSidney Kimmel Comprehensive Cancer Center
Aug 5, 2022
Advanced Malignant Solid Tumor Trial in Hangzhou (biological, other, drug, procedure)
Recruiting
- Advanced Malignant Solid Tumor
- iNeo-Vac-P01
- +3 more
-
Hangzhou, Zhejiang, ChinaRun Run Shaw Hospital Affiliated to Zhejiang University School o
Apr 25, 2021
Advanced Malignant Solid Tumors Trial in Nanchang (Neoantigen peptide vaccine, Neoantigen-based DC immune preparation)
Not yet recruiting
- Advanced Malignant Solid Tumors
- Neoantigen peptide vaccine
- Neoantigen-based DC immune preparation
-
Nanchang, Jiangxi, ChinaFirst Affiliated Hospital of Nanchang University
Mar 1, 2023
Breast Adenocarcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7 Trial in United States
Recruiting
- Breast Adenocarcinoma
- +7 more
- Multi-epitope HER2 Peptide Vaccine TPIV100
- +5 more
-
Scottsdale, Arizona
- +26 more
Aug 17, 2022
Adrenal Cortical Carcinoma, Medullary Thyroid Cancer, Thymic Neuroendocrine Carcinoma Trial in Shanghai (individualized mRNA
Not yet recruiting
- Adrenal Cortical Carcinoma
- +3 more
- individualized mRNA neoantigen vaccine (mRNA-0523-L001)
-
Shanghai, Shanghai, ChinaRuijin hospital, Shanghai Jiao-Tong University School of Medicin
Nov 19, 2023
Metastatic Colorectal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7 Trial in
Recruiting
- Metastatic Colorectal Adenocarcinoma
- +5 more
- Imiquimod
- +5 more
-
Houston, TexasM D Anderson Cancer Center
Aug 26, 2022
Diffuse Intrinsic Pontine Glioma Trial in Beijing (Histone H3.3-K27M Neoantigen Vaccine Therapy)
Recruiting
- Diffuse Intrinsic Pontine Glioma
- Histone H3.3-K27M Neoantigen Vaccine Therapy
-
Beijing, Beijing, ChinaBeijing Tiantan Hospital, Capital Medical University
Jul 18, 2022
Pancreatic Tumor Trial in Shanghai (Personalized neoantigen vaccine)
Recruiting
- Pancreatic Tumor
- Personalized neoantigen vaccine
-
Shanghai, Shanghai, ChinaChanghai Hospital
Mar 8, 2022
High Risk Cancer, Pancreatic Cancer Trial in Baltimore (KRAS peptide vaccine)
Recruiting
- High Risk Cancer
- Pancreatic Cancer
- KRAS peptide vaccine
-
Baltimore, MarylandSidney Kimmel Comprehensive Cancer Center
Jun 1, 2022
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8
Recruiting
- Anatomic Stage III Breast Cancer AJCC v8
- +129 more
- Cyclophosphamide
- +3 more
-
Jacksonville, FloridaMayo Clinic in Florida
Apr 8, 2022
Pancreatic Cancer, Pancreas Cancer, Cancer of the Pancreas Trial in Baltimore, Saint Louis (biological, device, procedure)
Active, not recruiting
- Pancreatic Cancer
- +2 more
- Personalized neoantigen DNA vaccine
- +2 more
-
Baltimore, Maryland
- +1 more
Sep 15, 2021
Pancreatic Cancer Trial in Herlev (drug, radiation, biological)
Not yet recruiting
- Pancreatic Cancer
- Nivolumab
- +3 more
-
Herlev, DenmarkHerlev & Gentofte University Hospital, Denmark
Feb 8, 2023
Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer Trial in United States (GRT-C903, GRT-R904, nivolumab)
Recruiting
- Non-Small Cell Lung Cancer
- +4 more
- GRT-C903
- +3 more
-
Phoenix, Arizona
- +13 more
Jan 30, 2023
NSCLC, EGFR Gene Mutation Trial in Nanjing (neo-antigen vaccine)
Recruiting
- NSCLC
- EGFR Gene Mutation
- neo-antigen vaccine
-
Nanjing, ChinaThe Comprehensive Cancer Centre of Nanjing Drum Tower Hospital,
Oct 19, 2023
Pancreatic Cancer Trial in Shanghai (Adebrelimab, mRNA tumor vaccines)
Not yet recruiting
- Pancreatic Cancer
- Adebrelimab
- mRNA tumor vaccines
-
Shanghai, Shanghai, ChinaDepartment of Pancreatic Surgery, Fudan University Shanghai Canc
Dec 4, 2023
Solid Tumor, Adult, EphA2 Overexpression, KRAS G12V Trial in Beijing (KRAS-EphA-2-CAR-DC, Abraxane, Cyclophosphamide)
Recruiting
- Solid Tumor, Adult
- +4 more
- KRAS-EphA-2-CAR-DC
- +3 more
-
Beijing, Beijing, ChinaBiotherapeutic Department of Chinsese PLA Gereral Hospital
Nov 29, 2022